| SD-Fhem1+/+ |
mean corpuscular volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
female |
0 days
| 3 |
55.6 |
fl |
1.96 |
3.4 |
automated blood analysis |
0.0 |
0 |
104874 |
2989 |
| SD-Fhem1+/+ |
blood monocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
male |
0 days
| 3 |
0.3 |
x 1000 cells/ul |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104901 |
2989 |
| SD-Fhem1+/+ |
red blood cell distribution width- standard deviation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
female |
0 days
| 3 |
26.1 |
% |
1.67 |
2.9 |
automated blood analysis |
0.0 |
0 |
104910 |
2989 |
| SD-Fhem1+/+ |
red blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
female |
0 days
| 3 |
7.2 |
x 10E6 cells/ul |
0.46 |
0.8 |
automated blood cell counting method |
0.0 |
0 |
104838 |
2989 |
| SD-Fhem1+/+ |
blood protein measurement |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood total protein amount |
male |
0 days
| 3 |
644.0 |
g/dl |
9.24 |
16.0 |
automated blood analysis |
0.0 |
0 |
104953 |
2989 |
| SD-Fhem1+/+ |
blood protein measurement |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood total protein amount |
female |
0 days
| 3 |
651.0 |
g/dl |
57.16 |
99.0 |
automated blood analysis |
0.0 |
0 |
104954 |
2989 |
| SD-Fhem1+/+ |
blood eosinophil count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
female |
0 days
| 3 |
2.1 |
% |
0.52 |
0.9 |
automated blood analysis |
0.0 |
0 |
104894 |
2989 |
| SD-Fhem1+/+ |
blood uric acid level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood uric acid amount |
female |
0 days
| 3 |
2.47 |
mg/dl |
1.25 |
2.16 |
automated blood analysis |
0.0 |
0 |
104974 |
2989 |
| SD-Fhem1+/+ |
blood lymphocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
male |
0 days
| 3 |
3.8 |
x 1000 cells/ul |
0.58 |
1.0 |
automated blood analysis |
0.0 |
0 |
104897 |
2989 |
| SD-Fhem1+/+ |
blood aspartate aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood aspartate transaminase amount |
male |
0 days
| 3 |
130.3 |
U/l |
5.83 |
10.1 |
automated blood analysis |
0.0 |
0 |
104929 |
2989 |
| SD-Fhem1+/+ |
plasma direct bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
female |
0 days
| 3 |
0.4 |
umol/l |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104946 |
2989 |
| SD-Fhem1+/+ |
blood glucose level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood glucose amount |
male |
0 days
| 3 |
147.6 |
mg/dl |
3.12 |
5.4 |
automated blood analysis |
0.0 |
0 |
104965 |
2989 |
| SD-Fhem1+/+ |
blood globulin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood globulin amount |
male |
0 days
| 3 |
310.0 |
g/dl |
1.15 |
2.0 |
automated blood analysis |
0.0 |
0 |
104961 |
2989 |
| SD-Fhem1+/+ |
mean platelet volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
female |
0 days
| 3 |
8.5 |
fl |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104866 |
2989 |
| SD-Fhem1+/+ |
white blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
male |
0 days
| 3 |
6.5 |
x 1000 cells/ul |
0.81 |
1.4 |
automated blood cell counting method |
0.0 |
0 |
104833 |
2989 |
| SD-Fhem1+/+ |
blood globulin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood globulin amount |
female |
0 days
| 3 |
296.0 |
g/dl |
34.64 |
60.0 |
automated blood analysis |
0.0 |
0 |
104962 |
2989 |
| SD-Fhem1+/+ |
blood lymphocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
female |
0 days
| 3 |
57.1 |
% |
4.56 |
7.9 |
automated blood analysis |
0.0 |
0 |
104886 |
2989 |
| SD-Fhem1+/+ |
blood alanine aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alanine transaminase amount |
male |
0 days
| 3 |
47.3 |
U/l |
1.79 |
3.1 |
automated blood analysis |
0.0 |
0 |
104925 |
2989 |
| SD-Fhem1+/+ |
blood gamma-glutamyltransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood gamma-glutamyltransferase amount |
female |
0 days
| 3 |
1.0 |
U/l |
0.0 |
0.0 |
automated blood analysis |
0.0 |
0 |
104934 |
2989 |
| SD-Fhem1+/+ |
plasma direct bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
male |
0 days
| 3 |
0.2 |
umol/l |
0.06 |
0.1 |
automated blood analysis |
0.0 |
0 |
104945 |
2989 |
| SD-Fhem1+/+ |
blood hemoglobin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
female |
0 days
| 3 |
1320.0 |
g/dl |
75.63 |
131.0 |
automated blood analysis |
0.0 |
0 |
104854 |
2989 |
| SD-Fhem1+/+ |
mean platelet volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
male |
0 days
| 3 |
8.7 |
fl |
0.17 |
0.3 |
automated blood analysis |
0.0 |
0 |
104865 |
2989 |
| SD-Fhem1+/+ |
red blood cell distribution width-coefficient of variation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
male |
0 days
| 3 |
17.3 |
% |
0.4 |
0.7 |
automated blood analysis |
0.0 |
0 |
104913 |
2989 |
| SD-Fhem1+/+ |
blood eosinophil count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
male |
0 days
| 3 |
1.0 |
% |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104893 |
2989 |
| SD-Fhem1+/+ |
blood alanine aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alanine transaminase amount |
female |
0 days
| 3 |
36.3 |
U/l |
1.85 |
3.2 |
automated blood analysis |
0.0 |
0 |
104926 |
2989 |
| SD-Fhem1+/+ |
blood gamma-glutamyltransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood gamma-glutamyltransferase amount |
male |
0 days
| 3 |
1.3 |
U/l |
0.35 |
0.6 |
automated blood analysis |
0.0 |
0 |
104933 |
2989 |
| SD-Fhem1+/+ |
blood alkaline phosphatase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alkaline phosphatase amount |
male |
0 days
| 3 |
84.7 |
U/l |
17.9 |
31.0 |
automated blood analysis |
0.0 |
0 |
104937 |
2989 |
| SD-Fhem1+/+ |
mean corpuscular hemoglobin concentration |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
male |
0 days
| 3 |
3367.0 |
g/dl |
3.46 |
6.0 |
automated blood analysis |
0.0 |
0 |
104881 |
2989 |
| SD-Fhem1+/+ |
blood monocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
monocyte quantity |
female |
0 days
| 3 |
4.5 |
% |
0.52 |
0.9 |
automated blood analysis |
0.0 |
0 |
104890 |
2989 |
| SD-Fhem1+/+ |
blood lymphocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
female |
0 days
| 3 |
3.3 |
x 1000 cells/ul |
0.75 |
1.3 |
automated blood analysis |
0.0 |
0 |
104898 |
2989 |
| SD-Fhem1+/+ |
platelet distribution width |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
female |
0 days
| 3 |
9.5 |
fl |
0.29 |
0.5 |
automated blood analysis |
0.0 |
0 |
104918 |
2989 |
| SD-Fhem1+/+ |
plasma indirect bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
male |
0 days
| 3 |
0.4 |
umol/l |
0.06 |
0.1 |
automated blood analysis |
0.0 |
0 |
104949 |
2989 |
| SD-Fhem1+/+ |
plasma indirect bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
female |
0 days
| 3 |
0.1 |
umol/l |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104950 |
2989 |
| SD-Fhem1+/+ |
hematocrit |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
male |
0 days
| 3 |
43.4 |
% |
0.92 |
1.6 |
automated blood analysis |
0.0 |
0 |
104857 |
2989 |
| SD-Fhem1+/+ |
mean corpuscular hemoglobin |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
male |
0 days
| 3 |
16.9 |
pg |
0.17 |
0.3 |
automated blood analysis |
0.0 |
0 |
104877 |
2989 |
| SD-Fhem1+/+ |
blood eosinophil count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
female |
0 days
| 3 |
0.1 |
x 1000 cells/ul |
0.0 |
0.0 |
automated blood analysis |
0.0 |
0 |
104906 |
2989 |
| SD-Fhem1+/+ |
blood urea nitrogen level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood urea nitrogen amount |
female |
0 days
| 3 |
670.0 |
mg/dl |
17.32 |
30.0 |
automated blood analysis |
0.0 |
0 |
104970 |
2989 |
| SD-Fhem1+/+ |
mean corpuscular hemoglobin |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
female |
0 days
| 3 |
18.3 |
pg |
0.46 |
0.8 |
automated blood analysis |
0.0 |
0 |
104878 |
2989 |
| SD-Fhem1+/+ |
red blood cell distribution width- standard deviation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
male |
0 days
| 3 |
25.5 |
% |
0.29 |
0.5 |
automated blood analysis |
0.0 |
0 |
104909 |
2989 |
| SD-Fhem1+/+ |
platelet distribution width |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
male |
0 days
| 3 |
9.8 |
fl |
0.4 |
0.7 |
automated blood analysis |
0.0 |
0 |
104917 |
2989 |
| SD-Fhem1+/+ |
blood creatine kinase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood creatine kinase amount |
female |
0 days
| 3 |
35.0 |
IU/l |
1.5 |
2.6 |
automated blood analysis |
0.0 |
0 |
104982 |
2989 |
| SD-Fhem1+/+ |
blood hemoglobin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
male |
0 days
| 3 |
1460.0 |
g/dl |
28.87 |
50.0 |
automated blood analysis |
0.0 |
0 |
104853 |
2989 |
| SD-Fhem1+/+ |
hematocrit |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
female |
0 days
| 3 |
39.9 |
% |
1.91 |
3.3 |
automated blood analysis |
0.0 |
0 |
104858 |
2989 |
| SD-Fhem1+/+ |
blood monocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
female |
0 days
| 3 |
0.3 |
x 1000 cells/ul |
0.06 |
0.1 |
automated blood analysis |
0.0 |
0 |
104902 |
2989 |
| SD-Fhem1+/+ |
blood eosinophil count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
male |
0 days
| 3 |
0.06 |
x 1000 cells/ul |
0.01 |
0.01 |
automated blood analysis |
0.0 |
0 |
104905 |
2989 |
| SD-Fhem1+/+ |
blood lymphocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
male |
0 days
| 3 |
58.5 |
% |
3.41 |
5.9 |
automated blood analysis |
0.0 |
0 |
104885 |
2989 |
| SD-Fhem1+/+ |
blood monocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
monocyte quantity |
male |
0 days
| 3 |
4.6 |
% |
0.06 |
0.1 |
automated blood analysis |
0.0 |
0 |
104889 |
2989 |
| SD-Fhem1+/+ |
platelet-large cell ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
female |
0 days
| 3 |
14.8 |
% |
0.87 |
1.5 |
automated blood analysis |
0.0 |
0 |
104922 |
2989 |
| SD-Fhem1+/+ |
blood alkaline phosphatase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alkaline phosphatase amount |
female |
0 days
| 3 |
36.0 |
U/l |
17.9 |
31.0 |
automated blood analysis |
0.0 |
0 |
104938 |
2989 |
| SD-Fhem1+/+ |
blood glucose level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood glucose amount |
female |
0 days
| 3 |
115.2 |
mg/dl |
14.55 |
25.2 |
automated blood analysis |
0.0 |
0 |
104966 |
2989 |
| SD-Fhem1+/+ |
blood albumin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood albumin amount |
male |
0 days
| 3 |
335.0 |
g/dl |
9.81 |
17.0 |
automated blood analysis |
0.0 |
0 |
104957 |
2989 |
| SD-Fhem1+/+ |
mean corpuscular volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
male |
0 days
| 3 |
50.3 |
fl |
0.52 |
0.9 |
automated blood analysis |
0.0 |
0 |
104873 |
2989 |
| SD-Fhem1+/+ |
platelet count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet quantity |
male |
0 days
| 3 |
1106.3 |
x 1000 /ul |
86.83 |
150.4 |
automated blood analysis |
0.0 |
0 |
104861 |
2989 |
| SD-Fhem1+/+ |
red blood cell distribution width-coefficient of variation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
female |
0 days
| 3 |
14.6 |
% |
1.91 |
3.3 |
automated blood analysis |
0.0 |
0 |
104914 |
2989 |
| SD-Fhem1+/+ |
mean corpuscular hemoglobin concentration |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
female |
0 days
| 3 |
3303.0 |
g/dl |
42.15 |
73.0 |
automated blood analysis |
0.0 |
0 |
104882 |
2989 |
| SD-Fhem1+/+ |
blood aspartate aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood aspartate transaminase amount |
female |
0 days
| 3 |
114.7 |
U/l |
8.31 |
14.4 |
automated blood analysis |
0.0 |
0 |
104930 |
2989 |
| SD-Fhem1+/+ |
white blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
female |
0 days
| 3 |
5.7 |
x 1000 cells/ul |
0.64 |
1.1 |
automated blood cell counting method |
0.0 |
0 |
104834 |
2989 |
| SD-Fhem1+/+ |
red blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
male |
0 days
| 3 |
8.6 |
x 10E6 cells/ul |
0.12 |
0.2 |
automated blood cell counting method |
0.0 |
0 |
104837 |
2989 |
| SD-Fhem1+/+ |
blood albumin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood albumin amount |
female |
0 days
| 3 |
355.0 |
g/dl |
23.67 |
41.0 |
automated blood analysis |
0.0 |
0 |
104958 |
2989 |
| SD-Fhem1+/+ |
blood creatine kinase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood creatine kinase amount |
male |
0 days
| 3 |
36.7 |
IU/l |
4.39 |
7.6 |
automated blood analysis |
0.0 |
0 |
104981 |
2989 |
| SD-Fhem1+/+ |
platelet count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet quantity |
female |
0 days
| 3 |
1152.3 |
x 1000 /ul |
118.82 |
205.8 |
automated blood analysis |
0.0 |
0 |
104862 |
2989 |
| SD-Fhem1+/+ |
blood urea nitrogen level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood urea nitrogen amount |
male |
0 days
| 3 |
780.0 |
mg/dl |
28.87 |
50.0 |
automated blood analysis |
0.0 |
0 |
104969 |
2989 |
| SD-Fhem1+/+ |
blood uric acid level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood uric acid amount |
male |
0 days
| 3 |
4.04 |
mg/dl |
0.14 |
0.25 |
automated blood analysis |
0.0 |
0 |
104973 |
2989 |
